Sonoma Pharmaceuticals, Inc. (SNOA) Earnings History
Net Loss22 years of earnings data (2005–2026) · Currently unprofitable on a TTM basis
Loading earnings history...
Sonoma Pharmaceuticals, Inc. (SNOA) Earnings Overview
As of June 28, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) reported trailing twelve-month net income of -$3M, reflecting +32.3% year-over-year growth. The company earned $-1.80 per diluted share over the past four quarters, with a net profit margin of -16.3%.
Looking at the long-term picture, SNOA's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2017.
Sonoma Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SSKN (-$6M net income, -20.4% margin), DERM (-$10M net income, -18.5% margin), PRPH (-$15M net income, -339.3% margin), SNOA has outperformed on profitability metrics. Compare SNOA vs SSKN →
SNOA Earnings vs Peers
Earnings metrics vs comparable public companies
SNOA Historical Earnings Data (2005–2026)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2026 | -$3M | +8.2% | -$2M | $-1.89 | -16.3% | -12.6% |
| 2025 | -$3M | +28.5% | -$4M | $-2.79 | -24.2% | -26.0% |
| 2024 | -$5M | +6.1% | -$5M | $-5.32 | -38.0% | -36.9% |
| 2023 | -$5M | -1.3% | -$5M | $-15.18 | -38.8% | -34.4% |
| 2022 | -$5M | -28.8% | -$6M | $-19.17 | -40.3% | -46.6% |
| 2021 | -$4M | -19.4% | -$3M | $-23.65 | -21.2% | -18.5% |
| 2020 | -$3M | +72.0% | -$7M | $-22.40 | -18.5% | -41.2% |
| 2019 | -$12M | +17.7% | -$11M | $-127.68 | -62.2% | -59.3% |
| 2018 | -$14M | -254.5% | -$14M | $-284.66 | -86.0% | -85.2% |
| 2017 | $9M | +191.3% | -$13M | $-221.70 | 72.3% | -101.2% |
| 2016 | -$10M | -23.9% | -$15M | $-117.81 | -108.5% | -157.0% |
| 2015 | -$8M | -319.6% | -$7M | $-130.06 | -59.2% | -48.1% |
| 2014 | $4M | +168.8% | -$6M | $117.39 | 27.3% | -44.3% |
| 2013 | -$5M | +25.9% | -$3M | $-585.02 | -35.1% | -21.8% |
| 2012 | -$7M | +7.8% | -$6M | $-393.82 | -57.5% | -50.7% |
| 2011 | -$8M | +3.4% | -$8M | $-468.66 | -81.5% | -76.9% |
| 2010 | -$8M | +53.4% | -$8M | $-509.82 | -111.8% | -108.9% |
| 2009 | -$18M | +13.2% | -$17M | $-1434.28 | -327.7% | -321.2% |
| 2008 | -$20M | -2.8% | -$22M | $-5040.00 | -530.4% | -584.7% |
| 2007 | -$20M | +14.4% | -$19M | $-11686.50 | -435.5% | -428.9% |
| 2006 | -$23M | -39.7% | -$21M | $-8766.22 | -893.9% | -806.9% |
| 2005 | -$17M | - | -$16M | $-6507.87 | -1219.0% | -1202.9% |
Download Data
Export SNOA earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
21+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SNOA — Frequently Asked Questions
Quick answers to the most common questions about buying SNOA stock.
What is SNOA earnings per share (EPS)?
SNOA trailing twelve-month (TTM) diluted EPS is $-1.80, reflecting +32.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2005 to 2026 is available in the table on this page.
What is Sonoma Pharmaceuticals, Inc.'s net income?
Sonoma Pharmaceuticals, Inc. (SNOA) trailing twelve-month net income is $-3M as of 2026. Earnings grew +32.3% year-over-year.
Is SNOA profitable?
SNOA is not currently profitable on a TTM basis, reporting a net loss of $-3M. Net margin is -16.3%. Investors should monitor for a return to profitability.
What is SNOA's earnings growth rate?
SNOA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2005 to 2026.
What are SNOA's profit margins?
Sonoma Pharmaceuticals, Inc. net profit margin is -16.3%, operating margin is -12.6%, and gross margin is +38.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -84.6%.
Is SNOA growing earnings?
Yes, SNOA earnings are accelerating — EPS growth of +32.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-3M. Earnings momentum is strengthening.
What was SNOA's best earnings year?
Sonoma Pharmaceuticals, Inc.'s highest annual net income on record is $9M, achieved in fiscal year 2017. Earnings history on this page spans 2005 to 2026 and includes all annual and quarterly figures.
What were SNOA's earnings last quarter?
SNOA's most recent reported quarter was Q4 2026. Net income was $-581000.00 with diluted EPS of $-0.33. For a full breakdown of all quarters, see the quarterly earnings table on this page.